{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/67105af848726944170ab1fe/688055b9498abee416ef990a?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Amber Salzman: Epigenetic Editing Aims to Refine Personalized Genetic Medicine","description":"<p>With recent safety setbacks in gene therapy underscoring the risks of genetic medicine, Amber Salzman, PhD, is charting a different course. After 25 years in big pharma, she now leads Epicrispr, where their Gene Expression Modulation System (GEMS) fine-tunes gene activity to tackle diseases too complex for traditional gene replacement, including Duchenne muscular dystrophy. On <em>Behind the Breakthroughs</em>, Salzman shares how epigenomic modulation could open new frontiers in treatment.</p><p><br></p><p>Produced and hosted by Jonathan D. Grinstein, PhD</p><p><br></p><p>Audio mixed and mastered by David Mosely</p><p><br></p><p>Brought to you by Inside Precision Medicine (SAGE Publishing)</p>","author_name":"Inside Precision Medicine"}